Skip to main content
Premium Trial:

Request an Annual Quote

Qlucore, Clarivate to Integrate Analytics Software for Multiomics Data

NEW YORK – Qlucore said Monday that it will integrate its flagship Omics Explorer software with Clarivate's MetaCore bioinformatics analysis platform for pathway analysis, enabling researchers to interpret and dig down into multiomics data more easily.

Lund, Sweden-based Qlucore's Omics Explorer provides fast, simple, visual analysis of measured data from a wide range of sources and instruments. MetaCore offers manually curated content for drug development, including validated pathway data to identify and analyze novel biomarkers, targets, and mechanisms of action.

Publicly traded, London-based Clarivate is an analytics firm formed in 2016 after Thomson Reuters sold its intellectual property and science business to two private equity firms.

"The combination of Qlucore Omics Explorer and MetaCore will make it easier and faster for research scientists to obtain clear and validated results," Qlucore President Carl-Johan Ivarsson said in a statement.

"Partnering with Qlucore will enhance the experience of researchers and aid the acceleration of scientific innovation," added Gavin Coney, VP for channels and alliances in the science group at Clarivate.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.